NASDAQ:NUVA NuVasive (NUVA) Stock Forecast, Price & News $39.75 0.00 (0.00%) (As of 09/11/2023) Add Compare Share Share Today's Range$39.75▼$39.7550-Day Range$38.12▼$43.0852-Week Range$35.17▼$49.53VolumeN/AAverage Volume1.16 million shsMarket Capitalization$2.08 billionP/E Ratio79.50Dividend YieldN/APrice Target$50.75 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media NuVasive MarketRank™ ForecastAnalyst RatingHold2.18 Rating ScoreUpside/Downside27.7% Upside$50.75 Price TargetShort InterestHealthy10.98% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 2 Articles This WeekInsider TradingN/AProj. Earnings Growth16.67%From $2.22 to $2.59 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.20 out of 5 starsMedical Sector431st out of 976 stocksMedical Devices Industry6th out of 8 stocks 3.1 Analyst's Opinion Consensus RatingNuVasive has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on 2 buy ratings, 9 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $50.75, NuVasive has a forecasted upside of 27.7% from its current price of $39.75.Amount of Analyst CoverageNuVasive has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted10.98% of the outstanding shares of NuVasive have been sold short.Short Interest Ratio / Days to CoverNuVasive has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in NuVasive has recently decreased by 10.70%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNuVasive does not currently pay a dividend.Dividend GrowthNuVasive does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NUVA. Previous Next 1.3 News and Social Media Coverage News SentimentNuVasive has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for NuVasive this week, compared to 4 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NuVasive insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.53% of the stock of NuVasive is held by insiders. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for NuVasive are expected to grow by 16.67% in the coming year, from $2.22 to $2.59 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NuVasive is 79.50, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.63.Price to Earnings Ratio vs. SectorThe P/E ratio of NuVasive is 79.50, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 155.14.Price to Book Value per Share RatioNuVasive has a P/B Ratio of 2.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About NuVasive (NASDAQ:NUVA) StockNuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California. As of September 1, 2023, NuVasive, Inc. operates as a subsidiary of Globus Medical, Inc.Read More NUVA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NUVA Stock News HeadlinesSeptember 27, 2023 | finance.yahoo.comGlobus Medical and NuVasive to Sponsor and Participate at EUROSPINE 2023September 26, 2023 | americanbankingnews.comNuVasive (NASDAQ:NUVA) Coverage Initiated by Analysts at StockNews.comSeptember 28, 2023 | UNKNOWN (Ad)The Bio-Tech Stock That Needs Your Attention!There a Few Opportunities Like This Stock! Sign Up Today And Get Our NExt Bio-Tech Alert!September 5, 2023 | finance.yahoo.comShould You Investigate NuVasive, Inc. (NASDAQ:NUVA) At US$39.75?September 4, 2023 | msn.comGlobus Medical merges with spine technology company NuvasiveSeptember 1, 2023 | baystreet.caGlobus Subsides on Merger with NuVasiveSeptember 1, 2023 | finance.yahoo.comGlobus Medical Completes Merger with NuVasiveAugust 31, 2023 | finance.yahoo.comWhy NuVasive (NUVA) is a Top Growth Stock for the Long-TermSeptember 28, 2023 | UNKNOWN (Ad)The Bio-Tech Stock That Needs Your Attention!There a Few Opportunities Like This Stock! Sign Up Today And Get Our NExt Bio-Tech Alert!August 31, 2023 | msn.comNuVasive/Globus Medical spread widens amid notice of FTC meeting (update)August 30, 2023 | seekingalpha.comNuVasive/Globus Medical spread widens amid notice of FTC closed door meetingAugust 29, 2023 | marketwatch.comGoosehead Insurance Shares Rise 17% After Move to SmallCap 600August 28, 2023 | msn.comNuVasive gains amid Nasdaq delisting notice for Globus Medical dealAugust 18, 2023 | seekingalpha.comNuVasive: 6.6% Spread With Globus Deal Still Not EnoughAugust 13, 2023 | theglobeandmail.comNUVA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NuVasive, Inc. Is Fair to ShareholdersAugust 7, 2023 | markets.businessinsider.comTruist Financial Remains a Hold on NuVasive (NUVA)August 4, 2023 | markets.businessinsider.comNuVasive Announces Second Quarter 2023 Financial ResultsAugust 3, 2023 | msn.comNuVasive Non-GAAP EPS of $0.56 beats by $0.01, revenue of $317.8M misses by $5.32MJuly 24, 2023 | finance.yahoo.comNuVasive Announces Conference Call and Webcast of Second Quarter 2023 ResultsJuly 21, 2023 | morningstar.comNuVasive Inc NUVA Stock QuoteJuly 20, 2023 | msn.comNuvasive/Globus Medical deal spread widens amid report FTC considering lawsuitJuly 19, 2023 | msn.comTruist Securities Maintains Nuvasive (NUVA) Hold RecommendationJuly 18, 2023 | finance.yahoo.comSMAIO: First-Half 2023 Sales up +203% to €4.0 MillionJuly 17, 2023 | markets.businessinsider.comNuVasive (NUVA) Receives a Hold from Truist FinancialJuly 15, 2023 | markets.businessinsider.comNuVasive (NUVA) Receives a Buy from RBC CapitalJuly 6, 2023 | finance.yahoo.comNUVA - NuVasive, Inc.June 25, 2023 | latimes.comFinalist: Gregory JacksonSee More Headlines Receive NUVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NuVasive and its competitors with MarketBeat's FREE daily newsletter. Email Address NUVA Company Calendar Last Earnings8/02/2023Today9/28/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical Devices Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:NUVA CUSIP67070410 CIK1142596 Webwww.nuvasive.com Phone(858) 909-1800Fax800-475-9134Employees3,000Year Founded1997Price Target and Rating Average Stock Price Forecast$50.75 High Stock Price Forecast$58.00 Low Stock Price Forecast$45.00 Forecasted Upside/Downside+27.7%Consensus RatingHold Rating Score (0-4)2.18 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)$0.50 Trailing P/E Ratio79.50 Forward P/E Ratio17.91 P/E GrowthN/ANet Income$40.41 million Net Margins2.32% Pretax Margin3.41% Return on Equity12.17% Return on Assets4.88% Debt Debt-to-Equity Ratio0.50 Current Ratio1.25 Quick Ratio0.65 Sales & Book Value Annual Sales$1.23 billion Price / Sales1.70 Cash Flow$4.96 per share Price / Cash Flow8.01 Book Value$17.02 per share Price / Book2.34Miscellaneous Outstanding Shares52,449,000Free Float52,171,000Market Cap$2.08 billion OptionableOptionable Beta1.07 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. J. Christopher Barry (Age 50)CEO & Director Comp: $3.08MMr. Matthew K. Harbaugh (Age 53)Principal Accounting Officer, CFO & Exec. VP Comp: $1.37MMr. Dale A. Wolf (Age 43)Sr. VP of Global Operations Comp: $782.6kMr. Nathaniel B. Sisitsky Esq. (Age 48)Sr. VP, Gen. Counsel & Corp. Sec. Comp: $842.84kMr. Michael Farrington (Age 39)Sr. VP of People & Culture Comp: $626.46kMr. Ryan DonahoeSr. VP & Chief Technology OfficerMs. Juliet C. CunninghamVP of Investor RelationsMr. Sean FreemanSr. VP of Strategy & Corp. Devel.Ms. Lisa PecoraVP & Head of Global Commercial Fin.Ms. Aviva McPherronSr. VP of Information TechnologyMore ExecutivesKey CompetitorsQuanterixNASDAQ:QTRXGemini TherapeuticsNASDAQ:GMTXPacific Biosciences of CaliforniaNASDAQ:PACBOmnicellNASDAQ:OMCLHarmony BiosciencesNASDAQ:HRMYView All CompetitorsInstitutional OwnershipAlberta Investment Management CorpBought 27,625 shares on 8/24/2023Ownership: 0.550%California State Teachers Retirement SystemSold 1,651 shares on 8/21/2023Ownership: 0.121%Teachers Retirement System of The State of KentuckyBought 955 shares on 8/21/2023Ownership: 0.037%Osaic Holdings Inc.Sold 417 shares on 8/21/2023Ownership: 0.003%Nuveen Asset Management LLCSold 15,572,660 shares on 8/16/2023Ownership: 0.291%View All Institutional Transactions NUVA Stock - Frequently Asked Questions Should I buy or sell NuVasive stock right now? 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 9 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NUVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NUVA, but not buy additional shares or sell existing shares. View NUVA analyst ratings or view top-rated stocks. What is NuVasive's stock price forecast for 2023? 11 analysts have issued 12 month target prices for NuVasive's shares. Their NUVA share price forecasts range from $45.00 to $58.00. On average, they predict the company's stock price to reach $50.75 in the next twelve months. This suggests a possible upside of 27.7% from the stock's current price. View analysts price targets for NUVA or view top-rated stocks among Wall Street analysts. How have NUVA shares performed in 2023? NuVasive's stock was trading at $41.24 at the start of the year. Since then, NUVA stock has decreased by 3.6% and is now trading at $39.75. View the best growth stocks for 2023 here. When is NuVasive's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our NUVA earnings forecast. How were NuVasive's earnings last quarter? NuVasive, Inc. (NASDAQ:NUVA) announced its quarterly earnings data on Wednesday, August, 2nd. The medical device company reported $0.56 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.56. The medical device company had revenue of $317.80 million for the quarter, compared to analysts' expectations of $322.53 million. NuVasive had a net margin of 2.32% and a trailing twelve-month return on equity of 12.17%. The business's revenue for the quarter was up 2.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.47 earnings per share. What ETFs hold NuVasive's stock? ETFs with the largest weight of NuVasive (NASDAQ:NUVA) stock in their portfolio include IQ Merger Arbitrage ETF (MNA), ProShares Merger ETF (MRGR), Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Health Care Equipment ETF (XHE), Vanguard S&P Small-Cap 600 Value ETF (VIOV), SPDR S&P 600 Small CapValue ETF (SLYV), iShares S&P Small-Cap 600 Value ETF (IJS) and Syntax Stratified SmallCap ETF (SSLY). How will NuVasive's stock buyback program work? NuVasive declared that its Board of Directors has authorized a share repurchase plan on Tuesday, November 9th 2021, which authorizes the company to repurchase $100,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to purchase up to 3.5% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's board of directors believes its stock is undervalued. What guidance has NuVasive issued on next quarter's earnings? NuVasive updated its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.27 billion-$1.30 billion, compared to the consensus revenue estimate of $1.29 billion. What is Chris Barry's approval rating as NuVasive's CEO? 59 employees have rated NuVasive Chief Executive Officer Chris Barry on Glassdoor.com. Chris Barry has an approval rating of 88% among the company's employees. What other stocks do shareholders of NuVasive own? Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), Intel (INTC), Alibaba Group (BABA), (MDVN) (MDVN), Micron Technology (MU), Bank of America (BAC), Gilead Sciences (GILD) and Applied Materials (AMAT). What is NuVasive's stock symbol? NuVasive trades on the NASDAQ under the ticker symbol "NUVA." Who are NuVasive's major shareholders? NuVasive's stock is owned by many different retail and institutional investors. Top institutional shareholders include KRYGER CAPITAL Ltd (4.51%), Alpine Associates Management Inc. (3.31%), Dimensional Fund Advisors LP (2.97%), Paradice Investment Management LLC (2.60%), Westchester Capital Management LLC (2.05%) and Geode Capital Management LLC (2.02%). Insiders that own company stock include James Christopher Barry, Lucas Vitale and Massimo Calafiore. View institutional ownership trends. How do I buy shares of NuVasive? Shares of NUVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is NuVasive's stock price today? One share of NUVA stock can currently be purchased for approximately $39.75. How much money does NuVasive make? NuVasive (NASDAQ:NUVA) has a market capitalization of $2.08 billion and generates $1.23 billion in revenue each year. The medical device company earns $40.41 million in net income (profit) each year or $0.50 on an earnings per share basis. How many employees does NuVasive have? The company employs 3,000 workers across the globe. Does NuVasive have any subsidiaries? The following companies are subsidiares of NuVasive: Biotronic NeuroNetwork, Ellipse Technologies, NuVasive Clinical Services Monitoring Inc., NuVasive Japan KK, NuVasive Specialized Orthopedics Inc., NuVasive Technology International Limited, SafePassage, Simplify Medical, and Vertera Spine.Read More How can I contact NuVasive? NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The official website for the company is www.nuvasive.com. The medical device company can be reached via phone at (858) 909-1800, via email at investorrelations@nuvasive.com, or via fax at 800-475-9134. This page (NASDAQ:NUVA) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NuVasive, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.